Rural farming populations in northern Rwanda consuming high-carbohydrate diets display virtually no cases of obesity

Overview Debates Related claims Topics

GLP-1 receptor agonist medications suppress appetite by targeting neural signaling pathways that regulate hunger and body weight settling points

In the United States, approximately 42% of adults are classified as obese

Approximately 50% to 60% of patients prescribed GLP-1 receptor agonist medications discontinue treatment within a few years

Over 1,000 distinct genetic loci have been associated with obesity risk in human genome-wide association studies

Rapid weight loss from GLP-1 receptor agonists often includes substantial reductions in skeletal muscle mass alongside fat loss

Populations in northern Rwanda experience sharp increases in obesity and type 2 diabetes following migration into urban environments

Adult obesity rates in the United States quadrupled between the mid-twentieth century and the 2020s

Approximately 72% of adults in the United States are classified as either overweight or obese based on body mass index

Heritability studies estimate that genetic variation explains between 30% and 70% of population-level body weight variation

Known obesity-associated genetic variants collectively account for between 6% and 17% of total variance in body weight

Diets high in refined sugar drive cellular oxidative stress, insulin resistance, and membrane dysfunction

Modern wheat is hybridized to contain higher amounts of gluten proteins and amylopectin A than ancient wheat strains

Forty-five percent of United States adolescents are classified as overweight or obese

Sam Tallent lost 120 pounds after quitting alcohol consumption and using the prescription medication Mounjaro

Andrew Huberman ingests carbohydrates such as fruit and starches following intensive resistance training sessions to replenish muscular glycogen

Excess body weight and obesity represent major modifiable risk factors for obstructive sleep apnea

Meaningful weight reduction reduces the apnea-hypopnea index in individuals whose obstructive sleep apnea is driven by excess adiposity

Participants taking Calocurb in a six-month clinical trial lost approximately 10 pounds of body fat and gained two pounds of muscle

In a nine-month study where Calocurb was stopped at six months, participants maintained their weight loss without rebound weight regain during a 12-week post-treatment period

In a six-month clinical trial of 150 participants with BMIs between 25 and 35, participants taking Calocurb lost an average of 5.5% of body weight